All In Biotech

Investigational drug · Phase 3

CTP-543

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alopecia Areata.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

21

Any phase or sponsor naming "CTP-543"

First trial start

2019

Apr 4, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "CTP-543", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Alopecia Areata

Approved drugs for the same conditions: Alopecia areata · Immunology and inflammation

Largest trials

Live from ClinicalTrials.gov: studies naming "CTP-543" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 6 on PubMed

Also in development for Alopecia Areata

  • VC005Phase 35 trials

    Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis

  • RezpegaldesleukinNKTR-358, REZPEGPhase 34 trials

    Nektar Therapeutics · Moderate-to-Severe Atopic Dermatitis, Moderate to Severe Atopic Dermatitis, Alopecia Areata

  • ADX-914bempikibartPhase 22 trials

    Q32 Bio Inc. · Atopic Dermatitis, Alopecia Areata

  • LY4005130Phase 22 trials

    Eli Lilly · Alopecia Areata, Vitiligo, Non-Segmental Vitiligo (NSV)

  • LAD603Phase 21 trial

    Almirall, S.A. · Alopecia Areata

  • NXC736Phase 21 trial

    NEXTGEN Bioscience · Alopecia Areata

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.